Lonaprisan Explained

Lonaprisan (INN, USAN) (developmental code names ZK-230211, BAY 86-5044, ZK-PRA) is a synthetic, steroidal antiprogestogen which was under development by Bayer HealthCare Pharmaceuticals for the treatment of endometriosis, dysmenorrhea, and breast cancer but was discontinued.^{[1] [2] [3]} It is a potent and highly selective silent antagonist of the progesterone receptor (PR).^[4] The drug reached phase II clinical trials prior to its discontinuation.

See also

• Mifepristone
• Onapristone
• Ulipristal acetate
• Vilaprisan

External links

• Web site: Lonaprisan . U.S. National Library of Medicine. Drug Information Portal.

Notes and References

1. Web site: Lonaprisan - AdisInsight. adisinsight.springer.com.
2. Whitaker LH, Williams AR, Critchley HO . Selective progesterone receptor modulators . Curr. Opin. Obstet. Gynecol. . 26 . 4 . 237–42 . 2014 . 24950125 . 10.1097/GCO.0000000000000082 . 37474964 .
3. Pluchino N, Freschi L, Wenger JM, Streuli I . Innovations in classical hormonal targets for endometriosis . Expert Rev Clin Pharmacol . 9 . 2 . 317–27 . 2016 . 26645363 . 10.1586/17512433.2016.1129895 . 8624056 .
4. Busia L, Faus H, Hoffmann J, Haendler B . The antiprogestin Lonaprisan inhibits breast cancer cell proliferation by inducing p21 expression . Mol. Cell. Endocrinol. . 333 . 1 . 37–46 . 2011 . 21138753 . 10.1016/j.mce.2010.11.034 . 12818061 .